Gene therapy for inflammatory and autoimmune diseases
Gene therapy for inflammatory and autoimmune diseases
This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressant...
New York, NY, United States
Overview Comments (1) Tagged publications
Background

Treatment of inflammatory and autoimmune diseases using gene therapy. Immunological reactions underlie a vast amount of medical conditions, including autoimmune disorders and transplant rejection. Most currently available immunosuppressive drugs are non-specific and have strong side effects, especially during prolonged usage. Antibody based therapies against immune cells are more directed, but tend to induce dangerously strong reactions during treatment. As a result, there is a pressing clinical need for new immunosuppressive agents.

Treating unwanted levels of CD40-mediated intracellular signaling using gene therapy

This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants. 

Applications:
– Highly specific inhibitors of antibody-mediated immune reactions.
– Can potentially be used to treat autoimmune diseases.
– Can be used as an immunosuppressive agent during organ transplants.

Advantages:
– Naturally derived and therefore not immunogenic.
– Highly specific and therefore has few side effects.
– Only targets B-cell proliferation, opening the possibility for highly directed therapy.

 
Lead InventorsSeth Lederman M.D., Dale M. Frank M.D., Aileen M. Cleary M.D.

RO
Raj Oswal 09.06.2017 08:03:18
Good

Similar innovations

Back
or
Back
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
Back
or
Back
  • Binding Partner to Tumor Suppressor
  • HAUSP (herpesvirus-associated ubiquitin-specific protease) as a novel p53-interacting deubiquitinase. HAUSP strongly stabilizes p53 by deubiquitinating p53, even in the presence of excess Mdm2. In addition, HAUSP binds directly to Mdm2 in such a way as to form a three-protein complex with p53 and, via this indirect interaction, p53 is also stabilized. The technology provides methods for screening HAUSP-p53 and HAUSP-Mdm2 interactions.
  • Read more
  • TherapeuticsMethods
  • New York, NY, United States
  • Stanford University
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 336

Send Us a Message